Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 4,001–4,100 of 4,108
Postmenopausal osteoporosis: standard diagnostic and therapeutic practice
Payer, J., Killinger, Z., Jackuliak, P., & Kužma, M. (2018) · Clinical Osteology · doi:10.36290/clo.2018.005 · Cited by 3
Růžičková, O. (2024) · Clinical Osteology · doi:10.36290/clo.2024.008
Lian, X.-D., Lee, J., Kang, S., Lee, J., Guan, Y., Lee, M.-K., Jung, K., & Li, Z. (2026) · Algal Research · doi:10.1016/j.algal.2026.104663
Ageing and Inequality Drive the Global Burden of Low Bone Mineral Density in Midlife and Older Women
Guo, M., Guo, M., Cai, M., et al. (2026) · Calcified Tissue International · doi:10.1007/s00223-026-01513-x
Management of bone health in cancer survivorship: a systematic review of clinical guidelines
Li, V. K. C., Cosgrove, S., Collins, K., Baden, P., Blennerhassett, R. C., Chan, B. A., Chan, L.-H., Day, D., Goodwin, B. C., Kwok, A., et al. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07924-8 · Cited by 2
Zhao, C.-X., Wang, R.-A., Feng, X. Y., et al. (2026) · Academic Radiology · doi:10.1016/j.acra.2026.03.001
Zimran, A., Botha, J., Eastell, R., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072537
Jyo, E. M., Ford, A., Yoon, H.-C., et al. (2025) · Open Journal of Radiology · doi:10.4236/ojrad.2025.151004
Lemey, C. (2017) · theses.fr (ABES) · doi:10.70675/14dca0fcze537z4da0z9184z9b59c260ea88
Roothaer, X. (2019) · theses.fr (ABES) · doi:10.70675/1e8ec67fz496ez4789zaed3zb7507d2233a6 · Cited by 3
Raveschot, C. (2018) · theses.fr (ABES) · doi:10.70675/291faa77z86dez473ez9917z89ac5cc0ccfe
Finianos, B. (2021) · theses.fr (ABES) · doi:10.70675/b42d813az5fd2z4029z9fe1z9e9b441fdd27 · Cited by 1
YILDIRIM, T. D., Erpek, E., Ulusoy, B. Ö., et al. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04349-3
“Osteoporosis was defined as a BMD of T-score ≤ − 2.5 SD at the lumbar spine, femoral neck, or total hip, and osteopenia as a BMD of T-score between − 1.0 and − 2.5 SD [12].”
InfluentialChen, S., Lü, R., Zhang, Y., Li, Y., Cao, X., Yang, H., & Lin, J. (2026) · International Journal of Endocrinology · doi:10.1155/ije/2237464
“These fractures are associated with a prolonged healing process and recovery time, greatly impairing patients’ quality of life and, in severe cases, leading to fatal outcomes [3].”
Osteoporose: diagnóstico densitométrico do T ao Z
Szejnfeld, V. L. (2025) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2025.24.3.62-65
Guo, Q., Li, J., Li, R., Xu, J., Huo, K., Pan, Y., & Wang, G. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13318-2
Kim, S. H., Choi, S., Cha, Y., Choi, E., & Jang, S. (2026) · Clinics in Orthopedic Surgery · doi:10.4055/cios25226
Meral, H. B., Aysal, F., Aliyeva, T., & Toplutaş, E. (2026) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20251090
“Osteoporosis is a skeletal disorder marked by low bone mass and structural deterioration, increasing fragility and fracture risk 1 .”
Jin, J., Yu, C., Chen, F., Li, J., Zhu, Y., Gao, Y., Wang, J., Ni, F., Yao, R., Chen, S., et al. (2026) · Immunity Inflammation and Disease · doi:10.1002/iid3.70449 · Cited by 1
“We considered additional covariates that may affect bone metabolism, based on previous studies and clinical guidelines [18, 26].”
Goranti, J., Sabesan, V., Sapkota, S., Prakash, V., & Murali, S. (2026) · Cureus · doi:10.7759/cureus.107708
“…of calcitonin has declined with the availability of newer antiresorptive agents, it continues to be prescribed in specific clinical settings, including acute hypercalcemia, refractory Paget’s disease of bone, and selected cases of osteoporosis where first-line therapies are contraindicated [1,3,6].”
Shaul, J., Bulterys, K., & Schepper, J. D. (2026) · Journal of Orthopaedic Experience & Innovation · doi:10.60118/001c.155444
Wan, Y., Sheng, X., Kan, W., Ji, J., Hu, H., Hu, J., & Lu, W. (2026) · Orthopedic Reviews · doi:10.52965/001c.161323 · Cited by 1
Ismaeel, A. M. D., Abbas, R. F., Mahmood, M. S., & Hameed, O. A. (2026) · Medical Journal of Babylon · doi:10.4103/mjbl.mjbl_796_23
The Sr-HA-loaded PLGA cage structure combines cells to construct a bone tissue repair unit
星, 義., Duan, G., Li, S., et al. (2026) · Regenerative Biomaterials · doi:10.1093/rb/rbag051
Propedêutica mínima no climatério Número 5 – Maio 2022
Baccaro, L. F., Paiva, L. C., Nasser, E. J., Valadares, A. L. R., da Silva, C. R., Nahás, E. A. P., Kulak, J., Rodrigues, M. A. H., Albernaz, M. A., Wender, M. C. O., et al. (2022) · Femina · doi:10.61622/0100-7254505202201 · Cited by 29
Liao, C.-C., Liao, K.-R., & Li, J.-M. (2026) · Clinical Gerontologist · doi:10.1080/07317115.2026.2675036 · Cited by 1
Gómez, L. A. P., Mantilla, Á. J. L., Ayala, M. C., Amaya, M. C., Rodríguez, J. M., Hernández-Quiñonez, D., & López, P. A. C. (2026) · Bone · doi:10.1016/j.bone.2026.117950
Li, X., Hu, M., & Shen, Y. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s599348
Sheikh, A. A. A. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2215_25 · Cited by 1
“[2] Despite its clinical significance, osteoporosis remains underdiagnosed and undertreated, especially in primary care settings.”
The utility of innominate dry bone weight in age estimation: A new pelvic aging method
Zurek-Ost, A. M., & Sorensen, M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350291
Giangregorio, L. (2026) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000001044 · Cited by 1
Management of Bone Health in Breast Cancer Survivors
Shivam, K., Allen, J., Aljabrain, F., Elliott, K.-J., Krishnamurthy, J., & Kelley, K. C. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00169
Çiçek, O., Kars, M. Y., Turgut, Z. İ., Akkar, I., Dogan, M. H., Saglam, M., & Kızılarslanoğlu, M. C. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00660-9
“Osteoporosis was diagnosed by DXA using WHO criteria and BMD values [28]: The coexistence of osteoporosis and sarcopenia was defined as osteosarcopenia, and the coexistence of osteoporosis and sarcopenic obesity was defined as osteosarcopenic obesity.”
Vitamin D and skeletal health: Practical approaches for bone health across the lifespan
ACCACHA, S., Silva, C., Talib, R., Ganji, V., Saadi, N., & Nwosu, B. U. (2026) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2026.101940
Age- and modality-specific trends in bone mineral density testing among women in Japan
Fujimaki, H., Uchida, K., Miyagi, M., et al. (2026) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2026.06.004
Franks, A. S., & Yett, E. S. (2026) · doi:10.21019/9781582123875.ch39
Yuk, H.-K., Oh, S. H., & Kim, D.-H. (2026) · Tomography · doi:10.3390/tomography12060089
“Dual-energy X-ray absorptiometry (DXA) remains the reference standard for assessing bone mineral density (BMD); however, its use in routine clinical practice is limited by underscreening, restricted accessibility, and the need for dedicated examinations [3,4].”
Keramati, M., Abadi, M. R. H., & Kontulainen, S. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349290
“Osteoporosis was defined as a T-score of ≤–2.5 at the left femoral neck or lumbar spine [34].”
InfluentialAdvances in Vitamin D for the Treatment of Osteoporosis: A Review
Sun, W. W., & Chen, H. (2026) · Biomedical Sciences · doi:10.11648/j.bs.20261202.12
Nagai, T., Hoshi, E., Ishikawa, K., Tsuchiya, K., Tani, S., Dodo, Y., Sakamoto, K., Kawate, N., & Kudo, Y. (2026) · Medicina · doi:10.3390/medicina62071220
“Estrogen levels begin to decline after approximately 40 years of age, leading to reduced estrogen receptor expression in osteocytes [22,23] and bone tissue [22].”
Almohammadi, A. A. (2026) · International Journal of Orthopaedic Surgery · doi:10.4103/ijors.ijors_1_26 · Cited by 4
Osteoporosis Management in Spine Surgery: Strategies for Optimizing Bone Health
Kulkarni, A. G., Deepika, J., Jayabalan, G., et al. (2026) · Springer eBooks · doi:10.1007/978-981-92-0619-3_32
Herrera, M. H., Martín, M. M., Gárate, G., de la Guerra-Sasián, L., González‐Quintanilla, V., Madera, J., Pérez‐Pereda, S., Valero, C., Olmos, J. M., Hernandez, J. M. D. L. T., et al. (2026) · Cephalalgia · doi:10.1177/03331024261453582
“We also asked patients if they were doing both the minimum recommended exercise to prevent osteoporosis (at least 30 min 3 days per week) 17 together with a minimum sun exposure and adequate vitamin D status (at least 5 – 15 min of sun exposure in face and arm during spring, summer and autumn).”
Perrella, L., Olmastroni, E., Mucherino, S., Rossi, A., Orlando, V., Casula, M., & Menditto, E. (2026) · Drugs & Aging · doi:10.1007/s40266-026-01312-x
“…“C08”, “C09”, “C01D”, “G04CA”) [10, 20], antidiabetic agents (ATC “A10B”) [12, 24], proton pump inhibitors (ATC “A02BC01”, “A02BC02”, “A02BC03”, “A02BC04”, “A02BC05”) [12, 25, 26] and anti-osteoporotic drugs (“M05BA”, “M05BB”, “M05BX”, “H05AA02”, “G03XC02”, “G03XC01”) [12, 27] were considered.”
Beraja, G. E., Kausel, A. M., Murase, J. E., Bordone, L. A., Sawaya, A. P., Vaccari, J. P. D. R., & Lev‐Tov, H. A. (2026) · International Journal of Women’s Dermatology · doi:10.1097/jw9.0000000000000262
Klockner, F. S., Jäckle, K., Malik, H. A., et al. (2026) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-026-10430-x
Chalouhy, G. A., Zakhem, E., Zunquin, G., et al. (2026) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2026.101724
Ahn, T. R., Kim, H. S., Cha, D. I., Yoon, Y. C., & Lee, J. H. (2026) · Skeletal Radiology · doi:10.1007/s00256-026-05299-9
“Osteopenia was defined as a T-score lower than − 1.0 but higher than − 2.5, based on the lowest central T-score [25, 26].”
InfluentialThe application of GLP-1 receptor agonists in obesity due to MC4R deficiency
Ding, M., Luo, Y., & Ji, L. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.58
Prevention of Osteoporotic Fractures in the Elderly: A Comprehensive Narrative Review
Almohammadi, A. A. (2026) · Journal of Orthopaedic Association of South Indian States · doi:10.4103/joasis.joasis_1_26
Pascual-Pastor, M., & Bru, M. B. (2026) · Nutrients · doi:10.3390/nu18142292 · Cited by 2
“Other consensus also recommend vitamin D supplementation at doses of 800–2000 IU/day for adults to maintain adequate vitamin D status [27,69,136].”
Alkhalaf, R., Saffaf, Y., & Alourfi, Z. (2026) · Journal of International Medical Research · doi:10.1177/03000605261467848
“7 4 – 8 Obesity is a medical condition of excessive fat accumulation that leads to negative effects on health.”
Lu, A. Z., Lam, F. M. H., Leung, J. C. S., Auyeung, T. W., Lee, J., Lai, K., Woo, J., & Kwok, T. C. Y. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70348 · Cited by 2
“Osteoporosis treatment is recommended only for individuals with T-scores ≤ − 2.5, or those with T-scores between − 1.0 and − 2.5 who have a 10-year fracture risk of ≥ 3% at the hip or ≥ 20% for any other osteoporotic fracture by FRAX [34].”
InfluentialProtocolo terapéutico de la osteopenia y la osteoporosis
Sureda, M. M. F., & Reniu, A. C. (2026) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2026.07.008
Hou, Z., Wu, Y., Zhan, L., Du, X., Xu, K., & Cui, R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145601
Nepal, S., Chaudhary, N., Ghimire, A., Gupta, R., Gyawali, P., Timilsina, M., & Bhandari, K. K. (2026) · Charak Journal of Health Research · doi:10.5005/cjhr-11037-0019
Li, Q., Shi, H., Hou, W., Gu, T., & Song, S. (2026) · Journal of orthopaedic surgery · doi:10.1177/10225536261470877
Klockner, F. S., von Stosch, D., Jäckle, K., et al. (2026) · Injury · doi:10.1016/j.injury.2026.113517
Ten-year re-validation of the fracture risk assessment tool (FRAX®) in Taiwan
Li, C., Liu, I. ‑., Liang, F., et al. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01745-2
“…thresholds identified herein were lower than both the global reference thresholds recommended by the National Osteoporosis Foundation [40, 41] In application, our proposed threshold ranges (9.0% to 9.5% for MOF and 4.0% to 4.5% for HF) are intended to guide community screening and…”
InfluentialHuang, X., 李, 函., Ling, K., Liu, Y., Li, Q., Zhao, T., Miao, J., Cai, J., Liu, J., Fan, Y., et al. (2026) · Journal of Biomedical Research · doi:10.7555/jbr.40.20260283
Bone mineral density among postmenopausal women in Basra
Habeeb, N. A., Abed, A. A., & Al-Rubaai, S. (2026) · Romanian Journal of Medical Practice · doi:10.37897/rjmp.2026.2.2
“When considering the combined effects of ageing and menopause, it has been shown that a woman’s bone density may decline by around 30% by the time she reaches the age of 80 [11].”
Liu, A., Liu, J., & Wu, Q. F. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01740-7
“The net reclassification improvement (NRI) and reclassification were assessed under the fixed 20% threshold based on the U.S. National Osteoporosis Foundation (NOF) [26].”
Fu, J., Xu, G., Chen, J., et al. (2026) · Frontiers in Surgery · doi:10.3389/fsurg.2026.1730811
Ishizaki, S., Tsunematsu, M., Furukawa, K., Taniai, T., Yamahata, Y., Haruki, K., Shirai, Y., Matsumoto, M., Onda, S., & Ikegami, T. (2026) · Surgery Today · doi:10.1007/s00595-026-03439-1
Alrashidi, M., Elbishari, H., Aljanahi, M., Amir‐Rad, F., Chaudhry, J., & Atieh, M. A. (2026) · Clinical and Experimental Dental Research · doi:10.1002/cre2.70423
“Regular monitoring of BMD is crucial for those diagnosed with osteopenia or osteoporosis to evaluate the effectiveness of treatment strategies (Cosman et al. 2014).”
Özbek, İ. C., & Okutan, İ. (2026) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-026-00440-x
Gil‐Ibáñez, B., Aznar, A. L., Barretina-Ginesta, M.-P., Quer, N., & Ramirez, P. T. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.104881 · Cited by 2
Sehgal, C., Bhutani, K., Rani, I., & Prasad, R. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01446-0
Wang, B., Tang, S., Tan, P., Mi, B., Chen, W., Gong, C., Yang, R., & Wei, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1899276
Riazanovskiy, K., Orlovs, D., Stepanova, J., Sineglazov, V. M., Platkājis, A., & Chumachenko, O. (2026) · Medicina · doi:10.3390/medicina62081518 · Cited by 2
“Vertebral compression fractures alone affect roughly one in four post-menopausal women, are associated with an age-adjusted one-year mortality hazard ratio above two, and carry a lifetime direct-cost burden comparable to that of hip fracture [1–3].”
Mizuno, N., Hamasaki, T., Kawaguchi, S., et al. (2026) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2026.07.012
Li, S., Pan, N., Niu, L., Yao, M., Zhao, S., Liu, C., & Li, D. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1903705
Performance Evaluation of Machine Learning Approaches for Automated Osteoporosis Detection
Saini, S. K. (2026) · International Conference on Sustainable Engineering and Technology Innovations (ICSETI) · doi:10.1109/icseti67678.2026.11636613
“The Dual-Energy X-ray Absorptiometry (DEXA) scan is the most precise and most commonly used technique that gives the Bone Mineral Density (BMD) of the hip and spine[19].”
Hajivalizadeh, S., Bashar, T. K., Maajani, K., Panahi, N., Fahimfar, N., Ostovar, A., Nabipour, I., & Khalagi, K. (2026) · Scientific Reports · doi:10.21203/rs.3.rs-10557840/v1
Xie, R., Liu, Y., Wu, Z., Huang, K., & Sun, Q. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02481-x
Automated opportunistic screening for low bone mineral density using routine CT brain imaging
Zhang, R., Panchal, N., Choong, H., et al. (2026) · Frontiers in Radiology · doi:10.3389/fradi.2026.1901958
Chen, F., He, P., Xu, W., Yu, D., & Luo, C. (2026) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-026-01749-5
Louka, P., Pitsillides, A. A., Koumas, M., Papacharalambous, C., Sophocleous, A., & Zanos, P. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyag044
Su, W., Xiao, S., Li, Y., & Yuan, Z. (2026) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2026.08.009
Kondameda, R., Kolliputi, S., & Kolliputi, N. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109126 · Cited by 1
Prieto, M. S., Romero-Dominguez, M., Orozco, R., Lilue, M., Lubián-López, D. M., González, S. P., Nieto, A., Coronado, P., Sánchez‐Borrego, R., Cano, A., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109101
Silva, I. C. J., Albergaria, B., Teixeira, B. C., & Lazaretti-Castro, M. (2026) · Archives of Osteoporosis · doi:10.1007/s11657-026-01734-5 · Cited by 1
“…for a substantial proportion of hip fractures among individuals aged 50 and older, their DXA screening rates remain disproportionately low, even within the age group recommended by international guidelines, which advise DXA screening for women aged 65 and older and men aged 70 and older [9, 10].”
Sun, Q., Yin, X., Yu, W., et al. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08185-1
Collier, J., Beck, B. R., Sabapathy, S., Collings, T., & Weeks, B. K. (2026) · Bone · doi:10.1016/j.bone.2026.118073
Mitsutake, S., & Hirata, T. (2026) · Osteoporosis International · doi:10.1007/s00198-026-08216-x
Kim, N. Y., Chung, Y. S., & Seo, S. K. (2026) · Journal of Menopausal Medicine · doi:10.6118/jmm.25151
“Bisphosphonates and denosumab are the most commonly used bone resorption inhibitors [1,2].”
InfluentialSaha, P., & MacGregor, A. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40344-6.00267-2
Taiwan joint consensus on the management of osteoporosis in patients with diabetes
Hwang, J., Chen, J., Tu, S., Wu, C., Wang, C., Han, D., Lee, C., Ouyang, C., Chen, S., Chen, C., et al. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.08.051
Prevention of Fracture Risk among Older Long-term Care Residents: A Prospective Study from India
Nanda, S. N., Tripathy, S., Gachhayat, A., & Kaushik, S. (2026) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_139_25
Krikelis, M. I., Divaris, E., Pappa, A., Kassi, E., Anagnostis, P. G., & Tournis, S. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109125
Gan, Y. S., Chiu, Y., Lee, K.-X. A., Liang, J.-H., Liong, G.-B., & Liong, S. (2026) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-026-02264-9
Kara, A. K., & Topçu, A. (2026) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1957314
Treatment sequence and treatment goals following osteoporotic vertebral compression fractures
Beall, D. P., Webb, J. R., Beall, O. A., Johnson, J. C., Kaufmann, A., Beall, S. E., Elghzali, A., Rahimi, M., & Khan, S. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33042-1.00004-1
Johnson, J. C., Beall, D. P., & Lake, A. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33042-1.00013-2
Beall, D. P., Beall, O. A., Webb, J. R., Johnson, J. C., & Mahmoud, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33042-1.00002-8
Case studies on the treatment of vertebral compression fractures and the underlying osteoporosis
Webb, J. R., Chong, C. C. W., & Beall, D. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33042-1.00014-4
Pham, P. T., Ha, T. M., Nguyen, H. Q., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-120565
Miscellaneous facts of osteoporosis and osteoporosis treatment
Beall, D. P., Webb, J. R., Beall, O. A., et al. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33042-1.00012-0
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.